Carlyle Group's acquisition of bluebird bio for $3 per share offers a potential but unlikely $600 million sales milestone by ...

In the last year, some drugmakers have pulled back from the sector, including Pfizer, which recently stopped selling its gene ...

Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc.

Erick J. Lucera to Step Down as CFO to pursue another opportunitySenior Vice President of Finance Amy Parison Appointed CFOCAMBRIDGE, Mass., ...

Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles ...

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

Currently, these technologies are subject to the EU’s strict GMO regulation, making their commercialisation in the bloc ...

The future of medicine is being shaped by a confluence of factors at play. If there are worries galore around drug resistant ...

Illumina Inc. and Nashville Biosciences, LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced that 250 ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

Role of AI in Drug Discovery AI is not just accelerating research; it's enabling scientists to uncover hidden patterns in ...

the biotech would push forward CRISPR-based drugs for a series of liver and brain diseases, beginning by filing for a first trial in under two years. It was, suffice to say, bold. Arbor had yet ...